Shy, Brian R. http://orcid.org/0000-0001-9569-3708
Vykunta, Vivasvan S. http://orcid.org/0000-0002-5409-8635
Ha, Alvin http://orcid.org/0000-0002-7092-9072
Talbot, Alexis http://orcid.org/0000-0001-6734-413X
Roth, Theodore L. http://orcid.org/0000-0002-3970-9573
Nguyen, David N. http://orcid.org/0000-0001-6808-2717
Pfeifer, Wolfgang G. http://orcid.org/0000-0002-5589-8415
Chen, Yan Yi http://orcid.org/0000-0003-3611-2621
Blaeschke, Franziska http://orcid.org/0000-0001-5770-4744
Shifrut, Eric http://orcid.org/0000-0001-6827-0128
Vedova, Shane
Mamedov, Murad R. http://orcid.org/0000-0002-1543-3330
Chung, Jing-Yi Jing
Li, Hong
Yu, Ruby
Wu, David http://orcid.org/0000-0002-9030-3667
Wolf, Jeffrey
Martin, Thomas G.
Castro, Carlos E. http://orcid.org/0000-0001-7023-6105
Ye, Lumeng
Esensten, Jonathan H.
Eyquem, Justin http://orcid.org/0000-0001-8262-1190
Marson, Alexander http://orcid.org/0000-0002-2734-5776
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01AI138962, T32GM007618, T32DK007418, L40AI140341, K08AI153767, 1S10OD025096-01A1, 1S10OD025096-01A1)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (L30TR002983)
Deutsche Forschungsgemeinschaft
Michelson Prize and Grants
Parker Institute for Cancer Immunotherapy
National Science Foundation (1933344)
Article History
Received: 13 August 2021
Accepted: 2 July 2022
First Online: 25 August 2022
Competing interests
: A.M. is a compensated cofounder, member of the boards of directors, and a member of the scientific advisory boards of Spotlight Therapeutics and Arsenal Biosciences. A.M. is a cofounder, member of the boards of directors, and a member of the scientific advisory board of Survey Genomics. A.M. is a compensated member of the scientific advisory board of NewLimit. A.M. owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma and Merck. A.M. has received fees from 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. J.E. is a compensated cofounder at Mnemo Therapeutics. J.E. is a compensated scientific advisor to Cytovia Therapeutics. J.E. own stocks in Mnemo Therapeutica and Cytovia Therapeutics. J.E. has received a consulting fee from Casdin Capital. The Eyquem laboratory has received research support from Cytovia Therapeutic and Takeda. J.E. is a holder of patents pertaining to but not resulting from this work. H.L and L.Y. are employees of Genscript Biotech Corporation. J.W. has received consulting fees from Teneobio and Adaptive Biotech. D.N.N. receives consulting fees and sits on the scientific advisory board of Navan Technologies. T.L.R. is a cofounder, holds equity in, and is a member of the Scientific Advisory Board of Arsenal Bioscience. Discounted reagents were provided by Genscript. B.R.S., V.S.V. and A.M. are inventors on patent applications based on the findings described in this paper, a subset of which have been licensed by the University of California. A.H., A.T., W.G.P., Y.Y.C., F.B., E.S., S.V., M.R.M., J.J.C., R.Y., D.W., T.G.M., C.E.C. and J.H.E. declare no competing interests.